

Electronic Acknowledgement Receipt

EFS ID:	11852533
Application Number:	10579007
International Application Number:	
Confirmation Number:	2230
Title of Invention:	System for treating and preventing breast cancer
First Named Inventor/Applicant Name:	Dennis L. Panicali
Customer Number:	45733
Filer:	Rachel Jean Mejdrich/Jacquelyn Hurd
Filer Authorized By:	Rachel Jean Mejdrich
Attorney Docket Number:	701278
Receipt Date:	17-JAN-2012
Filing Date:	19-OCT-2006
Time Stamp:	16:15:17
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 2200
RAM confirmation Number	3657
Deposit Account	121216
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Amendment Submitted/Entered with Filing of CPA/RCE	701278ROA.pdf	152516	no	4
			6541c1df2bc34ce4016c3e8ff471aa1cedbe3dda		
Warnings:					
Information:					
2	Information Disclosure Statement (IDS) Form (SB08)	701278IDS.pdf	235740	no	4
			75940867e533b0041b28f4f899a24455e092f556		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Information Disclosure Statement (IDS) Form (SB08)	701278IDS1449.pdf	64894	no	1
			85cab4939d23ce77627ebe5e65bbab1b4e9c8dee		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
4	Oath or Declaration filed	7012786decl.pdf	136165	no	3
			193871eacc0733357d42eb181ce59d4bb073fe2e		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
5	Non Patent Literature	Mohebtash.pdf	1028851	no	10
			5429beecc6687dfb6907ec420dee61ae1ba2d238		
Warnings:					
Information:					
6	Request for Continued Examination (RCE)	701278RCE.pdf	90701	no	2
			5207a4e57fd979c79c11bcc182a6389b2e4c6259		
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
7	Fee Worksheet (SB06)	fee-info.pdf	32041	no	2
			12455c55c137eff7ed54f88b0307c6a82755cc8c		
Warnings:					
Information:					
Total Files Size (in bytes):			1740908		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.